secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001999371-25-005877
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Q1 net loss $16.8M; cash $131.7M; PDUFA date Aug 15 for TNX-102 SL
------------------------------------------------------------------------

- Net loss $16.8M ($2.84/share) vs $14.9M ($535.72/share) in Q1 2024; product revenue $2.4M.
- Cash and equivalents $131.7M as of March 31, 2025; cash runway into Q2 2026.
- FDA PDUFA goal date Aug 15, 2025 for TNX-102 SL for fibromyalgia; if approved, first new drug in >15 years.
- Positive Phase 1 results for TNX-1500 anti-CD40L mAb; plans for Phase 2 in kidney transplant.
- Discontinued Phase 2 CATALYST study of TNX-1300 due to slow enrollment; not safety/efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125005877/0001999371-25-005877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125005877/tnxp-8k_051225.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-005877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer